Key Highlights
- FDA has greenlit Eli Lilly’s orforglipron, marketed under the brand name Foundayo, as a daily oral weight-loss medication
- April 6 launch scheduled through LillyDirect platform with $149 monthly pricing for out-of-pocket customers
- Wall Street forecasts 2026 revenue between $1.5B (Guggenheim estimate) and $2.8B (Citi projection), with peak revenue potential surpassing $40B
- Pre-launch stockpile of $1.5B designed to prevent supply chain problems experienced with injectable medications
- Consensus analyst price target for LLY stands at $1,221, with majority issuing Buy or Moderate Buy recommendations
Eli Lilly has achieved a major regulatory milestone with its oral GLP-1 medication. The FDA’s approval of orforglipron — marketed as Foundayo — establishes it as the pharmaceutical giant’s inaugural daily weight-loss tablet and positions it as a formidable competitor to Novo Nordisk’s market leadership.
During clinical studies, participants taking Foundayo experienced body weight reductions ranging from 12% to 15%. The medication operates through GLP-1 hormone targeting, utilizing the identical biological pathway as Novo’s injectable treatments Ozempic and Wegovy.
The company plans to initiate Foundayo distribution on April 6 via its LillyDirect service. Patients paying out-of-pocket will have access to the entry-level dosage at $149 monthly — strategically matching Ozempic’s price point.
Chief Executive David Ricks disclosed that regulatory submissions for Foundayo have been filed across more than 40 nations, indicating an extensive global expansion strategy is underway.
The Street’s response has been notably positive. Financial analysts are forecasting 2026 revenues spanning $1.5 billion to $2.8 billion, with Citi leading optimistic projections at $2.8B and estimating peak annual revenues could exceed $40 billion. J.P. Morgan anticipates sales climbing to $6 billion by 2027.
Bernstein adopted a more measured short-term outlook, highlighting that complimentary samples, reduced starting doses and pricing considerations might impact initial revenue performance, despite potentially strong prescription growth. Weekly new-patient enrollment figures will serve as the critical metric for market watchers.
Foundayo benefits from a production advantage. Manufacturing proves simpler compared to injectable GLP-1 medications, potentially enabling Lilly to expand capacity more rapidly — especially in global markets where injectables have encountered supply limitations.
Supply Chain Strategy
Lilly reports establishing $1.5 billion in pre-launch stockpiles, a strategic move addressing the availability challenges that affected its injectable medications Zepbound and Mounjaro. These shortages created opportunities for U.S. compounding facilities to distribute alternative versions. Lilly has subsequently pursued legal remedies against compounders and wellness facilities marketing products purportedly containing tirzepatide.
Novo Nordisk continues to compete aggressively. The Copenhagen-based pharmaceutical company has introduced subscription models and product modifications in response. UBS projects the combined oral drug offerings from both companies could reach approximately $5 billion in 2026, signaling rapid expansion within the obesity treatment sector.
Morningstar forecasts that oral obesity medications could comprise roughly one-third of a $180 billion worldwide market by 2034.
Strategic Deal and Wall Street Sentiment
Lilly is proceeding with the acquisition of Centessa Pharmaceuticals through a transaction initially valued near $6.3 billion, broadening its portfolio into sleep-wake disorder and narcolepsy treatments. A legal firm has initiated an investor investigation regarding the Centessa transaction procedures, potentially creating complications before deal completion.
Regarding institutional activity, Westend Capital Management established a fresh LLY position during Q4, acquiring 16,393 shares valued at approximately $17.6 million. LLY currently represents roughly 4.9% of Westend’s holdings.
The company delivered Q4 earnings per share of $7.54, surpassing analyst expectations of $7.48, with quarterly revenue reaching $19.29 billion versus consensus estimates of $17.85 billion. Revenue increased 42.6% compared to the prior year. Management established FY2026 EPS guidance between $33.50 and $35.00.
Among 30 analysts tracking the equity, 23 assign Buy ratings, four recommend Hold, and one advises Sell. The consensus price target registers at $1,221.26.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
